A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
Hiroshige Yoshioka(Kurashiki Central Hospital), K. Azuma(Kurume University), Nobuyuki Yamamoto(Wakayama Medical University), Toshiaki Takahashi(Shizuoka Cancer Center), Makoto Nishio(The Cancer Institute Hospital), Nobuyuki Katakami(Foundation for Biomedical Research and Innovation), Myung‐Ju Ahn(Samsung Medical Center), T. Hirashima(Osaka Prefectural Medical Center), Makoto Maemondo(Miyagi Prefectural Hospital Organization), S.W. Kim(Ulsan College), Mami Kurosaki(Kyowa Kirin (Japan)), Shiro Akinaga(Kyowa Kirin (Japan)), K. Park(Samsung Medical Center), C.-M. Tsai(Taipei Veterans General Hospital), Tomohide Tamura(National Cancer Center), Tetsuya Mitsudomi, Kazuhiko Nakagawa(Kindai University)
Cited by 117Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis